戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (right1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                           Transfusion rates did not change.
2 ges (p = 0.010), whereas genioglossus muscle responsiveness did not change.
3                                      Ghrelin concentrations did not change.
4  by 23% and did not change for 35-49 and >=50; Asian donors did not change.
5                                         Cellular ATP levels did not change.
6 re-HDTBR, cerebrovascular reactivity during and after HDTBR did not change.
7 m 7.39% to 8.85% (P < .001), whereas the contamination rate did not change and remained low.
8 in 18 levels declined by the end of treatment, sCD14 levels did not change, and sCD163, MCP-1, and IL-6 levels changed at
9 mbient PCO2 combined with 30 days of strict 6 degrees HDTBR did not change arterialized PCO2 levels.
10 olic and proanthocyanidin contents, and woody aroma profile did not change because of the film-treatment.
11  donors increased by 18%, 14%, and 27%; Hispanic donors <35 did not change but increased by 22% and 35% for 35-49 and >=5
12     During the maintenance phase, HAM-D-17 and MADRS scores did not change, but the mean IDS-SR score decreased from 38.8
13 /331 (69.8%) were methicillin resistant, and the proportion did not change by year.
14 htness/darkness, hue angle, and total color difference, but did not change chroma, yellowness/blueness, color index, and
15  post-SVR year 1; however, in patients with TT/TT, genotype did not change during and after DAA treatment.
16  likely to benefit from combination therapy, but vorinostat did not change ER expression at the level of detection of (18
17                     By contrast, randomly oriented mimetics did not change focal adhesion tension sensation or enrich for
18 5% for 35-49 and >=50; black donors <35 declined by 23% and did not change for 35-49 and >=50; Asian donors did not chang
19                                                    Mean IOP did not change from baseline to final visit in the overall co
20                         The performances of both procedures did not change in 168 patients with longitudinal MRI studies
21                                                    P-tau217 did not change in amyloid-beta-negative participants, or in p
22                      The number of antiglaucoma medications did not change in both groups (p > 0.05) and showed no signif
23 fter fluid bolus were similar, the arterial load parameters did not change in mean arterial pressure-nonresponders.
24 Quality of life improved in the 1500-mg arm at 12 weeks but did not change in the 3000-mg arm.
25                   Although the archetypal discovery process did not change markedly in the first seven decades of the ind
26          Repeated thawing and re-freezing up to three times did not change measured sNfL concentration significantly, eit
27                                               Empagliflozin did not change myocardial oxygen consumption or MEE.
28                     Between 2016 and 2019, hard coral cover did not change on deep reefs which remained dominated by turf
29                           The proportion of LT HIV-infected did not change over time (P-trend = 0.16).
30                           Administration at effective doses did not change plasma damage markers or the morphology of kid
31                   Moreover, overall sepsis risk was low and did not change significantly as a result of probiotics supple
32                                     P1 subtype distribution did not change significantly chronologically or geographicall
33                                                    Mean IOP did not change significantly from baseline to 12 and 24 month
34                                                   T2(water) did not change significantly in either group (intervention, P
35 s of the burden of first recurrences and in-hospital deaths did not change significantly.
36                                                    Zolpidem did not change the apnoea-hypopnoea index versus placebo (40.
37     Statistical adjustment for antiparkinson medication use did not change the findings.
38          Adjustment for donor and recipient characteristics did not change the findings.
39          Mutation of the putative PKA phosphorylation sites did not change the inhibitory effect of IBMX on THIK-1 curren
40  to control, a dialysate sodium concentration of 135 mmol/L did not change the left ventricular mass index, despite signi
41     The results indicated that FO replacement by dietary AM did not change the levels of most biochemical (ALB, AMY, TP a
42                                      Inhibition of Beclin 1 did not change the levels of several key inflammatory molecul
43      The abrupt and gradual temperature increase treatments did not change the microbial community composition as compare
44                                      Addition of BIV to TRI did not change the odds of bleeding for any risk strata.
45 t increase in bone formation rate (+30.7%, P = 0.0029), but did not change the ultimate force (P < 0.01).
46                          The daily rate of hospitalizations did not change throughout 2019 (-0.01% per day [95% CI: -0.04
47  down in response to predator cues, whereas hatchery salmon did not change travel speed.
48                                                 The program did not change trend in 30-day readmission (+0.19% readmissio
49  in both dams and offspring in a dose-dependent manner, but did not change TSH levels, weight, histology, or expression o
50 bility increased following 1 mg brexpiprazole treatment and did not change with 4 mg.
51 ith larger LVs (90% vs. 83%, P = 0.03), the PET specificity did not change with LV size (76% vs. 76%, P = 0.9).
52 s found elevated IL-6 levels correlated with mortality that did not change with tocilizumab administration.